Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,947 public trials 2,015 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Recruiting

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

NCT07101328

Conditions
B-cell Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +23 more
Locations
  • City of Hope Duarte, California, United States
  • University of Colorado Denver - School of Medicine - Anschutz Medical Campus Aurora, Colorado, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Yale University School of Medicine - Yale Cancer Center New Haven, Connecticut, United States
View all 50 locations
View Trial Details
Recruiting

To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

NCT07454187

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Henan Cancer Hospital Zhengzhou, Henan, China
  • The First Affiliated Hospital Of Soochow University Suzhou, Jiangsu, China
  • The Second Affiliated Hospital Of Xi an Jiaotong University (Xibei Hospital) Xi’an, Shanxi, China
  • The Second Affiliated Hospital Zhejiang University School Of Medicine Hangzhou, Zhejiang, China
View Trial Details
Recruiting

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

NCT05327894

Conditions
Acute Lymphoblastic Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +11 more
Locations
  • Hospital de Pediatría S.A.M.I.C. "Juan P. Garrahan" Buenos Aires, Argentina
  • Australian and New Zealand Children's Haematology/Oncology Group Clayton, Victoria, Australia
  • North Adelaide- Womens and Childrens Hospital Adelaide, Australia
  • Monash Children's Hosptial Clayton, Australia
View all 124 locations
View Trial Details
Recruiting

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

NCT05714839

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • GSK Investigational Site Bullhead City, Arizona, United States
  • GSK Investigational Site Pembroke Pines, Florida, United States
  • GSK Investigational Site Grand Rapids, Michigan, United States
  • GSK Investigational Site Chapel Hill, North Carolina, United States
View all 36 locations
View Trial Details
Recruiting

CAR-T Cell Therapy for ALL

NCT07695012

Conditions
Disease Attributes, Hematologic Diseases, Hemic and Lymphatic Diseases, +13 more
Locations
  • National University of Medical Sciences, Clinical Trial Unit Rawalpindi, Pakistan
View Trial Details
Recruiting

A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain

NCT07029737

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Research Site A Coruña, Spain
  • Research Site Alcorcón, Spain
  • Research Site Badalona, Spain
  • Research Site Barcelona, Spain
View all 22 locations
View Trial Details
Recruiting

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

NCT05077527

Conditions
AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, Blood-Borne Infections, +36 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of Illinois at Chicago Chicago, Illinois, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • Montefiore Medical Center - Moses Campus The Bronx, New York, United States
View Trial Details
Recruiting

A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

NCT06508983

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Beijing Chaoyang Hospital of Capital Medical University Beijing, Beijing Municipality, China
  • Guangzhou First People's Hospital Guangzhou, Guangdong, China
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
  • First Affiliated Hospital of Henan University of Science and Technology Luoyang, Henan, China
View Trial Details
Recruiting

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT06015880

Conditions
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Hemic and Lymphatic Diseases, High Grade B-Cell Lymphoma, +11 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Northwestern University Chicago, Illinois, United States
View Trial Details

Related conditions